Fine particulate matter (PM2.5) exposure drives early atherogenesis through a senescence-dependent mechanism: C57BL/6J mice inhaling concentrated ambient PM2.5 developed significant endothelial activation — measurable by increased leukocyte rolling and adhesion on intact vasculature — alongside senescence in peripheral blood mononuclear cells and endothelial progenitor cells (EPCs), confirmed by β-galactosidase activity and SASP gene expression. Critically, the senolytic combination of Dasatinib and Quercetin (DQ) reversed both cellular senescence markers and restored EPC tube-forming capacity while suppressing in vivo endothelial activation.
This finding matters because it mechanistically links air pollution to a well-characterized aging pathway — cellular senescence — and positions an already-clinically-available drug pair as a potential countermeasure. Quercetin is commercially accessible; Dasatinib is an FDA-approved leukemia drug. The DQ combination has prior human pilot data in idiopathic pulmonary fibrosis and diabetic kidney disease, lending translational plausibility. However, this is a mouse model with acute concentrated exposure, not chronic low-level human exposure, limiting direct extrapolation. Effect size quantification for in vivo endpoints remains underreported in the abstract. More importantly, Dasatinib carries significant immunosuppressive and cardiotoxic risks at therapeutic doses, making population-level prophylactic use premature. Still, this is a genuinely useful mechanistic advance: identifying senescence as a tractable early node in pollution-driven cardiovascular disease opens a new intervention window beyond emission controls. Confirmatory human studies — particularly in high-exposure urban populations — are urgently warranted.
